共 50 条
- [21] Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI TreatmentONCOLOGY, 2021, 99 (01) : 32 - 40Tseng, Jeng-SenHsu, Kuo-HsuanZheng, Zhe-RongYang, Tsung-YingChen, Kun-ChiehHuang, Yen-HsiangSu, Kang-YiYu, Sung-LiangChang, Gee-Chen
- [22] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment FailureJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S609 - S609Feng, Y.Zhu, H.Hu, X.Liu, Y.Xing, P.Wang, H.Ji, X.Dai, Z.Shi, Y.
- [23] Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer PatientsSCIENTIFIC REPORTS, 2016, 6Matsuo, NorikazuAzuma, KoichiSakai, KazukoHattori, SatoshiKawahara, AkihikoIshii, HidenobuTokito, TakaakiKinoshita, TakashiYamada, KazuhikoNishio, KazutoHoshino, Tomoaki
- [24] Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer PatientsScientific Reports, 6Norikazu MatsuoKoichi AzumaKazuko SakaiSatoshi HattoriAkihiko KawaharaHidenobu IshiiTakaaki TokitoTakashi KinoshitaKazuhiko YamadaKazuto NishioTomoaki Hoshino
- [25] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersCLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247Yu, Helena A.Arcila, Maria E.Rekhtman, NatashaSima, Camelia S.Zakowski, Maureen F.Pao, WilliamKris, Mark G.Miller, Vincent A.Ladanyi, MarcRiely, Gregory J.
- [26] Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer PatientsJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1201 - S1202Matsuo, NorikazuAzuma, KoichiSakai, KazukoKawahara, AkihikoIshii, HidenobuTokito, TakaakiKinoshita, TakashiYamada, KazuhikoNishio, KazutoHoshino, Tomoaki
- [27] Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumorsANNALS OF ONCOLOGY, 2017, 28Chen, Y-Y.Zhu, Q-Q.Dai, L-J.Ding, Z-Y.
- [28] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim PolymorphismJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970He, Y.Zhao, C.Li, X.Ren, S.Jiang, T.Zhang, J.Su, C.Chen, X.Cai, W.Gao, G.Li, W.Wu, F.Li, J.Zhao, J.Zhou, F.Hu, Q.Hirsch, F. R.Zhou, C.
- [29] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive diseaseJOURNAL OF CANCER, 2019, 10 (02): : 522 - 529Xu, QinghuaLiu, HuiMeng, ShuyanJiang, TaoLi, XuefeiLiang, ShixiongRen, ShengxiangZhou, Caicun
- [30] Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naive Advanced EGFR-Mutant Lung Adenocarcinoma PatientsONCOTARGETS AND THERAPY, 2021, 14 : 2139 - 2148Hsu, Kuo-HsuanHuang, Jing-WenTseng, Jeng-SenChen, Kuan-WenWeng, Yih-ChyangYu, Sung-LiangYang, Tsung-YingHuang, Yen-HsiangChen, Jeremy JwChen, Kun-ChiehChang, Gee-Chen